Volume 2, Issue 2, June 2023

View Volume 2, Issue 2, June 2023

Review: Coronavirus disease (COVID-19) in patients with hematologic malignancy
Cellular therapy in CLL/iNHL: Therapeutic agents in the pipeline
Evolving role of novel therapies in myeloma: T-cell engagers and antibody-drug conjugates
Acute myeloid leukemia induction in the age of novel therapeutic agents
Initiating venetoclax treatment: Clinical practice pearls

Published: 2023-06-07

Full Issue

Articles

Review: Coronavirus disease (COVID-19) in patients with hematologic malignancy

Inna Y. Gong, MD, PhD, FRCPC, Lisa K. Hicks, MD, MSc, FRCPC

5–10
- PDF (en)
- PDF (fr)
Cellular therapy in CLL/iNHL: Therapeutic agents in the pipeline

Christopher Lemieux, MD, FRCPC

12–14
- PDF (en)
- PDF (fr)
Evolving role of novel therapies in myeloma: T-cell engagers and antibody-drug conjugates

Alfredo de la Torre, MD

16–19
- PDF (en)
- PDF (fr)
Acute myeloid leukemia induction in the age of novel therapeutic agents

Nicholas Allen Forward, MD, MSc, FRCPC

21–25
- PDF (en)
- PDF (fr)
Initiating venetoclax treatment: Clinical practice pearls

Dwip Prajapati, MD, FRCPC

27–30
- PDF (en)
- PDF (fr)